HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows
Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut suggest near‑term downside risk, but the 13% YoY subscriber growth may support a longer‑term recovery.
Market read
HIMS shares fell over 15% to seven‑month lows after the earnings release, reflecting immediate market reaction.
What to watch
Potential cost reductions from lower marketing spend and future partnership opportunities.
Background
Hims & Hers Health is a telehealth provider whose performance is tied to consumer demand for weight‑loss drugs and subscriber growth.
Ticker impact
Hims & Hers reported a Q3 loss of $33 million, cut FY2026 EBITDA guidance and lowered Jefferies price target to $24.
downward pressure as the market prices in the loss and reduced outlook
The surprise loss, lowered guidance and price‑target reduction are fresh, material facts that typically trigger sell‑offs.
Market effects
Telehealth and digital health stocks may see heightened volatility amid GLP‑1 weight‑loss drug uncertainty.
U.S. markets could see a modest pullback in health‑tech indices.
Limited to U.S. listed telehealth firms; no immediate global ripple.
Counterpoint
If the GLP‑1 market stabilizes, HIMS could rebound on its subscriber base growth.
Key entities
- analystJefferies
Lowered price target to $24 and warned of volatility.
- analystNeedham
Attributed weaker quarter to reduced marketing spend.
